The 2020 Forbes China Innovation Summit officially opened in Chengdu on October 29. Hundreds of guests from all over the country gathered in Chengdu to discuss innovation and development in the new era around the theme of "New Breakthrough in Global Innovation". Guan Zhisheng, Director and Deputy General Manager of Hybribio Biotech, was invited to attend the meeting and participated in the roundtable dialogue session to give a speech. At the same time, the summit announced the "2020 Forbes China's Most Innovative Companies List" and "2020 Forbes China's List of Potential Listed Companies" awards and held a grand award ceremony. Hybribio Biotech was listed on the "2020 Forbes China's List of Potential Listed Companies ".

Basing on a global perspective, this summit focused on the theme of "New Breakthroughs in Global Innovation", and discussed innovation and development in the new era. Guan Zhisheng, Director and Deputy General Manager of Hybribio Biotech, Li Feng, Vice President of Longji's New Energy Business Group, Dong Xiangguo, Chief Information Officer and General Manager of Zhongwei Huilian, Han Yu, AK Medical Board Secretary, and He Fang, General Manager of Zhongmi Holdings, took the stage together, centered on the hot topic of "high-end manufacturing", and launched a wonderful roundtable dialogue with the theme of "new technology promotes the upgrading of China's high-end manufacturing". 

Nowadays, while promoting the quality and upgrading of China's manufacturing industry, new technologies are also affecting various traditional industries and emerging fields, bringing new impetus to the development and transformation of the real economy. As a leading developer and supplier of nucleic acid molecular diagnostic products in China, Mr. Guan said, the successful development of novel coronavirus detection reagents by the Hybribio team this year was mainly due to the continuous upgrading of the industry and technology accumulation in the past ten years. It was pointed out that the production system of the pharmaceutical industry is similar to high-end manufacturing in terms of large-scale production. It should not only continue to focus on precision and instrument automation, but also pay attention to the quality of the entire production process.

Hybribio is an important member of China's high-end manufacturing industry, and is accelerating the pace of corporate technology upgrading, building a service network and sample database, and striving to promote the implementation of the "Healthy China 2030" strategy and help the transformation and upgrade of the biomedical industry and social health services. 

After nearly 20 years of development, Hybribio Biotech has become a leading in vitro diagnostic reagent supplier and a leader in the third-party medical diagnostic field in China. To meet clinical needs, Hybribio targets infectious diseases such as genital tract infections and hepatitis B, genetic diseases such as thalassemia, deafness, fava bean disease, and eugenics projects such as premarital physical examinations and neonatal defects screening to develop nucleic acid molecular diagnostic products for a wide range of market application scenarios. Products are sold to more than 1,800 domestic medical institutions and more than 30 overseas countries and regions, providing integrated professional solutions for medical institutions.

Hybribio has established 25 medical laboratories to form a medical laboratory service network covering key cities across the country, so that more high-quality and convenient inspection services can be widely used for public health and improve the integration and development of "platform + reagent + service" which extends from the upstream industrial chain to downstream industrial chain.  

2020 Forbes China's List of Potential Listed Companies selected companies with operating income between RMB 10 million and RMB 1 billion from 2017 to 2019, and required that profitability was achieved in both 2018 and 2019. A total of 50 companies have entered the 2020 Forbes China's List of Potential Listed Companies, with a total market value of nearly 800 billion yuan. These companies have similar characteristics that the median revenue and profit growth rate in the three years has exceeded 100%, the debt ratio is relatively low, and robust expansion under an uncertain economic environment.

The rise of technology companies means that China's economic moat has been further broadened. Hybribio will continue to forge ahead, adhere to the high-quality development of path for scientific and technological innovation, and strive to become a leader in nucleic acid molecular diagnostics with strong technical strength and innovative capabilities in China.